+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Orphan Drugs Market by Therapeutic Area (Immunology, Infectious Diseases, Metabolic Disorders), Product Type (Biologics, Gene Therapy, Small-Molecule), Administration Route, Distribution Channel, Patient Type, Payer Type - Global Forecast 2025-2030- Product Image
Orphan Drugs Market by Therapeutic Area (Immunology, Infectious Diseases, Metabolic Disorders), Product Type (Biologics, Gene Therapy, Small-Molecule), Administration Route, Distribution Channel, Patient Type, Payer Type - Global Forecast 2025-2030- Product Image
Sale

Orphan Drugs Market by Therapeutic Area (Immunology, Infectious Diseases, Metabolic Disorders), Product Type (Biologics, Gene Therapy, Small-Molecule), Administration Route, Distribution Channel, Patient Type, Payer Type - Global Forecast 2025-2030

  • PDF Icon

    Report

  • 187 Pages
  • August 2025
  • Region: Global
  • 360iResearch™
  • ID: 5674387
UP TO OFF until Jan 01st 2026
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The orphan drugs market is rapidly evolving into a prime opportunity space for pharmaceutical and biotechnology leaders focused on high-value, innovation-driven therapeutic solutions for rare diseases. This transformation is underpinned by global shifts in regulation, patient engagement models, and technology adoption, making it essential for decision-makers to understand current dynamics and future directions.

Market Snapshot: Orphan Drugs Market Outlook

The Orphan Drugs Market grew from USD 216.80 billion in 2024 to USD 246.85 billion in 2025. It is expected to continue growing at a CAGR of 13.48%, reaching USD 463.09 billion by 2030. This sustained expansion is propelled by increased recognition of rare diseases, supportive global regulatory environments, and an active pipeline of advanced therapeutics. The market’s robust pace is fundamentally altering how industry players approach research, commercialization, and strategic partnerships in rare disease treatment.

Scope & Segmentation

This comprehensive analysis segments the orphan drugs market across multiple dimensions and details emerging technology use and global landscape shifts:

  • Therapeutic Areas: Immunology, infectious diseases, metabolic disorders, neurology, oncology
  • Product Types: Biologics (enzymes, monoclonal antibodies, recombinant proteins), gene therapy (non-viral and viral vectors), small molecules, tissue therapies
  • Administration Routes: Inhalation, injectable (intramuscular, intravenous, subcutaneous), oral, topical
  • Distribution Channels: Direct-to-patient programs, hospital pharmacy, online pharmacy, retail pharmacy
  • Patient Types: Adult, pediatric
  • Payer Types: Government programs, out-of-pocket, private insurance
  • Regions: Americas (with focused states in the US), Europe, Middle East & Africa, Asia-Pacific (with extensive country-level analysis)
  • Technologies: Targeted small molecules, advanced gene therapies, vector design, antibody engineering, recombinant protein platforms, and digital health integration
  • Companies Covered: F. Hoffmann-La Roche Ltd, Johnson & Johnson, Novartis AG, Pfizer Inc., Sanofi S.A., Bristol-Myers Squibb Company, Amgen Inc., Takeda Pharmaceutical Company Limited, AbbVie Inc., BioMarin Pharmaceutical Inc.

Key Takeaways for Senior Decision-Makers

  • Regulatory frameworks, including financial incentives and accelerated approval pathways, are increasing R&D investment and drawing both established pharmaceutical leaders and emerging biotechs toward rare disease drug development.
  • Innovation in gene editing, recombinant protein engineering, and cell-based therapies is enabling a diversified therapeutic portfolio, while digital health platforms facilitate adaptive clinical trial design and real-world evidence gathering.
  • Strategic collaborations, particularly between academia, contract manufacturers, and patient groups, are crucial in mitigating development costs, streamlining manufacturing requirements, and achieving clinical milestones more efficiently.
  • Patient engagement models and outcome-based agreements are shifting, with stakeholders prioritizing quality-of-life outcomes, adaptable endpoints, and targeted delivery that support sustainable reimbursement and patient access strategies.
  • Regional differences remain significant: Americas excel in biologics adoption and rapid regulatory advancement; Europe, Middle East, and Africa face fragmented approval pathways but are boosted by localized manufacturing investment; Asia-Pacific’s growth is fueled by government initiatives and cross-border partnerships.

Tariff Impact: Navigating 2025 U.S. Supply Chain Adjustments

Upcoming U.S. tariff changes in 2025 are set to impact orphan drug supply chains by introducing duties on imported pharmaceutical inputs. Companies are taking proactive steps, including supply chain diversification, contingency planning, and domestic manufacturing investments to protect production efficiency and cost controls. Engagements with policymakers aim to secure targeted tariff exemptions for essential therapies, ensuring stable patient access and viable financial models amidst evolving trade regulations.

Methodology & Data Sources

This report uses a rigorous mixed-method approach, combining stakeholder interviews (including industry executives, regulators, and patient groups) with an extensive review of peer-reviewed literature, financial disclosures, and regulatory filings. Quantitative insights are validated through triangulation and expert committee review, ensuring reliable analysis and actionable guidance.

Why This Report Matters

  • Offers strategic clarity for leaders seeking growth and competitive edge within complex, innovation-driven pharmaceutical segments.
  • Equips decision-makers with regionally-tailored insights, revealing the interplay between therapeutic advances, evolving payer models, and supply chain risks.
  • Enables proactive planning for regulatory shifts, collaboration opportunities, and technology investment—all critical for sustained leadership in the orphan drugs market.

Conclusion

The orphan drugs market presents unique strategic growth opportunities at the intersection of regulatory support, scientific advancement, and patient-centric approaches. Leaders who align innovation, operational agility, and cross-sector collaboration will be well positioned to realize the potential of next-generation rare disease therapeutics.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
5.1. Rising adoption of gene editing therapies reshaping treatment options for ultra rare diseases
5.2. Emergence of artificial intelligence platforms accelerating orphan drug discovery and repurposing initiatives
5.3. Expansion of patient-centric digital registries improving real world data collection for rare disease trials
5.4. Increase in strategic academia-industry collaborations driving accelerated development of niche orphan indications
5.5. Mounting payer scrutiny and novel outcome-based reimbursement models influencing market access for rare disease therapies
5.6. Surge in investment for cell and gene therapy manufacturing capacity to meet growing orphan drug demand
5.7. Regulatory harmonization efforts between major agencies expediting approval pathways for pediatric rare disease treatments
5.8. Intensifying competition among small biotech firms leveraging CRISPR for targeted therapies in genetically defined orphan diseases
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Orphan Drugs Market, by Therapeutic Area
8.1. Introduction
8.2. Immunology
8.3. Infectious Diseases
8.4. Metabolic Disorders
8.5. Neurology
8.6. Oncology
9. Orphan Drugs Market, by Product Type
9.1. Introduction
9.2. Biologics
9.2.1. Enzymes
9.2.2. Monoclonal Antibodies
9.2.3. Recombinant Proteins
9.3. Gene Therapy
9.3.1. Non-Viral Vector
9.3.2. Viral Vector
9.4. Small-Molecule
9.5. Tissue Therapy
10. Orphan Drugs Market, by Administration Route
10.1. Introduction
10.2. Inhalation
10.3. Injectable
10.3.1. Intramuscular
10.3.2. Intravenous
10.3.3. Subcutaneous
10.4. Oral
10.5. Topical
11. Orphan Drugs Market, by Distribution Channel
11.1. Introduction
11.2. Direct-To-Patient
11.3. Hospital Pharmacy
11.4. Online Pharmacy
11.5. Retail Pharmacy
12. Orphan Drugs Market, by Patient Type
12.1. Introduction
12.2. Adult
12.3. Pediatric
13. Orphan Drugs Market, by Payer Type
13.1. Introduction
13.2. Government Programs
13.3. Out-Of-Pocket
13.4. Private Insurance
14. Americas Orphan Drugs Market
14.1. Introduction
14.2. United States
14.3. Canada
14.4. Mexico
14.5. Brazil
14.6. Argentina
15. Europe, Middle East & Africa Orphan Drugs Market
15.1. Introduction
15.2. United Kingdom
15.3. Germany
15.4. France
15.5. Russia
15.6. Italy
15.7. Spain
15.8. United Arab Emirates
15.9. Saudi Arabia
15.10. South Africa
15.11. Denmark
15.12. Netherlands
15.13. Qatar
15.14. Finland
15.15. Sweden
15.16. Nigeria
15.17. Egypt
15.18. Turkey
15.19. Israel
15.20. Norway
15.21. Poland
15.22. Switzerland
16. Asia-Pacific Orphan Drugs Market
16.1. Introduction
16.2. China
16.3. India
16.4. Japan
16.5. Australia
16.6. South Korea
16.7. Indonesia
16.8. Thailand
16.9. Philippines
16.10. Malaysia
16.11. Singapore
16.12. Vietnam
16.13. Taiwan
17. Competitive Landscape
17.1. Market Share Analysis, 2024
17.2. FPNV Positioning Matrix, 2024
17.3. Competitive Analysis
17.3.1. F. Hoffmann-La Roche Ltd
17.3.2. Johnson & Johnson
17.3.3. Novartis AG
17.3.4. Pfizer Inc.
17.3.5. Sanofi S.A.
17.3.6. Bristol-Myers Squibb Company
17.3.7. Amgen Inc.
17.3.8. Takeda Pharmaceutical Company Limited
17.3.9. AbbVie Inc.
17.3.10. BioMarin Pharmaceutical Inc.
18. ResearchAI
19. ResearchStatistics
20. ResearchContacts
21. ResearchArticles
22. Appendix
List of Figures
FIGURE 1. ORPHAN DRUGS MARKET RESEARCH PROCESS
FIGURE 2. GLOBAL ORPHAN DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 3. GLOBAL ORPHAN DRUGS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 4. GLOBAL ORPHAN DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 5. GLOBAL ORPHAN DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2024 VS 2030 (%)
FIGURE 6. GLOBAL ORPHAN DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL ORPHAN DRUGS MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2030 (%)
FIGURE 8. GLOBAL ORPHAN DRUGS MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL ORPHAN DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2024 VS 2030 (%)
FIGURE 10. GLOBAL ORPHAN DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL ORPHAN DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2030 (%)
FIGURE 12. GLOBAL ORPHAN DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL ORPHAN DRUGS MARKET SIZE, BY PATIENT TYPE, 2024 VS 2030 (%)
FIGURE 14. GLOBAL ORPHAN DRUGS MARKET SIZE, BY PATIENT TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. GLOBAL ORPHAN DRUGS MARKET SIZE, BY PAYER TYPE, 2024 VS 2030 (%)
FIGURE 16. GLOBAL ORPHAN DRUGS MARKET SIZE, BY PAYER TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. AMERICAS ORPHAN DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 18. AMERICAS ORPHAN DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. UNITED STATES ORPHAN DRUGS MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 20. UNITED STATES ORPHAN DRUGS MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. EUROPE, MIDDLE EAST & AFRICA ORPHAN DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 22. EUROPE, MIDDLE EAST & AFRICA ORPHAN DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. ASIA-PACIFIC ORPHAN DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 24. ASIA-PACIFIC ORPHAN DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 25. ORPHAN DRUGS MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 26. ORPHAN DRUGS MARKET, FPNV POSITIONING MATRIX, 2024
FIGURE 27. ORPHAN DRUGS MARKET: RESEARCHAI
FIGURE 28. ORPHAN DRUGS MARKET: RESEARCHSTATISTICS
FIGURE 29. ORPHAN DRUGS MARKET: RESEARCHCONTACTS
FIGURE 30. ORPHAN DRUGS MARKET: RESEARCHARTICLES
List of Tables
TABLE 1. ORPHAN DRUGS MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL ORPHAN DRUGS MARKET SIZE, 2018-2024 (USD MILLION)
TABLE 4. GLOBAL ORPHAN DRUGS MARKET SIZE, 2025-2030 (USD MILLION)
TABLE 5. GLOBAL ORPHAN DRUGS MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
TABLE 6. GLOBAL ORPHAN DRUGS MARKET SIZE, BY REGION, 2025-2030 (USD MILLION)
TABLE 7. GLOBAL ORPHAN DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 8. GLOBAL ORPHAN DRUGS MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 9. GLOBAL ORPHAN DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2024 (USD MILLION)
TABLE 10. GLOBAL ORPHAN DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2025-2030 (USD MILLION)
TABLE 11. GLOBAL ORPHAN DRUGS MARKET SIZE, BY IMMUNOLOGY, BY REGION, 2018-2024 (USD MILLION)
TABLE 12. GLOBAL ORPHAN DRUGS MARKET SIZE, BY IMMUNOLOGY, BY REGION, 2025-2030 (USD MILLION)
TABLE 13. GLOBAL ORPHAN DRUGS MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2018-2024 (USD MILLION)
TABLE 14. GLOBAL ORPHAN DRUGS MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2025-2030 (USD MILLION)
TABLE 15. GLOBAL ORPHAN DRUGS MARKET SIZE, BY METABOLIC DISORDERS, BY REGION, 2018-2024 (USD MILLION)
TABLE 16. GLOBAL ORPHAN DRUGS MARKET SIZE, BY METABOLIC DISORDERS, BY REGION, 2025-2030 (USD MILLION)
TABLE 17. GLOBAL ORPHAN DRUGS MARKET SIZE, BY NEUROLOGY, BY REGION, 2018-2024 (USD MILLION)
TABLE 18. GLOBAL ORPHAN DRUGS MARKET SIZE, BY NEUROLOGY, BY REGION, 2025-2030 (USD MILLION)
TABLE 19. GLOBAL ORPHAN DRUGS MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2024 (USD MILLION)
TABLE 20. GLOBAL ORPHAN DRUGS MARKET SIZE, BY ONCOLOGY, BY REGION, 2025-2030 (USD MILLION)
TABLE 21. GLOBAL ORPHAN DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 22. GLOBAL ORPHAN DRUGS MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 23. GLOBAL ORPHAN DRUGS MARKET SIZE, BY BIOLOGICS, BY REGION, 2018-2024 (USD MILLION)
TABLE 24. GLOBAL ORPHAN DRUGS MARKET SIZE, BY BIOLOGICS, BY REGION, 2025-2030 (USD MILLION)
TABLE 25. GLOBAL ORPHAN DRUGS MARKET SIZE, BY ENZYMES, BY REGION, 2018-2024 (USD MILLION)
TABLE 26. GLOBAL ORPHAN DRUGS MARKET SIZE, BY ENZYMES, BY REGION, 2025-2030 (USD MILLION)
TABLE 27. GLOBAL ORPHAN DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2018-2024 (USD MILLION)
TABLE 28. GLOBAL ORPHAN DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2025-2030 (USD MILLION)
TABLE 29. GLOBAL ORPHAN DRUGS MARKET SIZE, BY RECOMBINANT PROTEINS, BY REGION, 2018-2024 (USD MILLION)
TABLE 30. GLOBAL ORPHAN DRUGS MARKET SIZE, BY RECOMBINANT PROTEINS, BY REGION, 2025-2030 (USD MILLION)
TABLE 31. GLOBAL ORPHAN DRUGS MARKET SIZE, BY BIOLOGICS, 2018-2024 (USD MILLION)
TABLE 32. GLOBAL ORPHAN DRUGS MARKET SIZE, BY BIOLOGICS, 2025-2030 (USD MILLION)
TABLE 33. GLOBAL ORPHAN DRUGS MARKET SIZE, BY GENE THERAPY, BY REGION, 2018-2024 (USD MILLION)
TABLE 34. GLOBAL ORPHAN DRUGS MARKET SIZE, BY GENE THERAPY, BY REGION, 2025-2030 (USD MILLION)
TABLE 35. GLOBAL ORPHAN DRUGS MARKET SIZE, BY NON-VIRAL VECTOR, BY REGION, 2018-2024 (USD MILLION)
TABLE 36. GLOBAL ORPHAN DRUGS MARKET SIZE, BY NON-VIRAL VECTOR, BY REGION, 2025-2030 (USD MILLION)
TABLE 37. GLOBAL ORPHAN DRUGS MARKET SIZE, BY VIRAL VECTOR, BY REGION, 2018-2024 (USD MILLION)
TABLE 38. GLOBAL ORPHAN DRUGS MARKET SIZE, BY VIRAL VECTOR, BY REGION, 2025-2030 (USD MILLION)
TABLE 39. GLOBAL ORPHAN DRUGS MARKET SIZE, BY GENE THERAPY, 2018-2024 (USD MILLION)
TABLE 40. GLOBAL ORPHAN DRUGS MARKET SIZE, BY GENE THERAPY, 2025-2030 (USD MILLION)
TABLE 41. GLOBAL ORPHAN DRUGS MARKET SIZE, BY SMALL-MOLECULE, BY REGION, 2018-2024 (USD MILLION)
TABLE 42. GLOBAL ORPHAN DRUGS MARKET SIZE, BY SMALL-MOLECULE, BY REGION, 2025-2030 (USD MILLION)
TABLE 43. GLOBAL ORPHAN DRUGS MARKET SIZE, BY TISSUE THERAPY, BY REGION, 2018-2024 (USD MILLION)
TABLE 44. GLOBAL ORPHAN DRUGS MARKET SIZE, BY TISSUE THERAPY, BY REGION, 2025-2030 (USD MILLION)
TABLE 45. GLOBAL ORPHAN DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2024 (USD MILLION)
TABLE 46. GLOBAL ORPHAN DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2025-2030 (USD MILLION)
TABLE 47. GLOBAL ORPHAN DRUGS MARKET SIZE, BY INHALATION, BY REGION, 2018-2024 (USD MILLION)
TABLE 48. GLOBAL ORPHAN DRUGS MARKET SIZE, BY INHALATION, BY REGION, 2025-2030 (USD MILLION)
TABLE 49. GLOBAL ORPHAN DRUGS MARKET SIZE, BY INJECTABLE, BY REGION, 2018-2024 (USD MILLION)
TABLE 50. GLOBAL ORPHAN DRUGS MARKET SIZE, BY INJECTABLE, BY REGION, 2025-2030 (USD MILLION)
TABLE 51. GLOBAL ORPHAN DRUGS MARKET SIZE, BY INTRAMUSCULAR, BY REGION, 2018-2024 (USD MILLION)
TABLE 52. GLOBAL ORPHAN DRUGS MARKET SIZE, BY INTRAMUSCULAR, BY REGION, 2025-2030 (USD MILLION)
TABLE 53. GLOBAL ORPHAN DRUGS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2024 (USD MILLION)
TABLE 54. GLOBAL ORPHAN DRUGS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2025-2030 (USD MILLION)
TABLE 55. GLOBAL ORPHAN DRUGS MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2024 (USD MILLION)
TABLE 56. GLOBAL ORPHAN DRUGS MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2025-2030 (USD MILLION)
TABLE 57. GLOBAL ORPHAN DRUGS MARKET SIZE, BY INJECTABLE, 2018-2024 (USD MILLION)
TABLE 58. GLOBAL ORPHAN DRUGS MARKET SIZE, BY INJECTABLE, 2025-2030 (USD MILLION)
TABLE 59. GLOBAL ORPHAN DRUGS MARKET SIZE, BY ORAL, BY REGION, 2018-2024 (USD MILLION)
TABLE 60. GLOBAL ORPHAN DRUGS MARKET SIZE, BY ORAL, BY REGION, 2025-2030 (USD MILLION)
TABLE 61. GLOBAL ORPHAN DRUGS MARKET SIZE, BY TOPICAL, BY REGION, 2018-2024 (USD MILLION)
TABLE 62. GLOBAL ORPHAN DRUGS MARKET SIZE, BY TOPICAL, BY REGION, 2025-2030 (USD MILLION)
TABLE 63. GLOBAL ORPHAN DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 64. GLOBAL ORPHAN DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 65. GLOBAL ORPHAN DRUGS MARKET SIZE, BY DIRECT-TO-PATIENT, BY REGION, 2018-2024 (USD MILLION)
TABLE 66. GLOBAL ORPHAN DRUGS MARKET SIZE, BY DIRECT-TO-PATIENT, BY REGION, 2025-2030 (USD MILLION)
TABLE 67. GLOBAL ORPHAN DRUGS MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2024 (USD MILLION)
TABLE 68. GLOBAL ORPHAN DRUGS MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2025-2030 (USD MILLION)
TABLE 69. GLOBAL ORPHAN DRUGS MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2024 (USD MILLION)
TABLE 70. GLOBAL ORPHAN DRUGS MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2025-2030 (USD MILLION)
TABLE 71. GLOBAL ORPHAN DRUGS MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2024 (USD MILLION)
TABLE 72. GLOBAL ORPHAN DRUGS MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2025-2030 (USD MILLION)
TABLE 73. GLOBAL ORPHAN DRUGS MARKET SIZE, BY PATIENT TYPE, 2018-2024 (USD MILLION)
TABLE 74. GLOBAL ORPHAN DRUGS MARKET SIZE, BY PATIENT TYPE, 2025-2030 (USD MILLION)
TABLE 75. GLOBAL ORPHAN DRUGS MARKET SIZE, BY ADULT, BY REGION, 2018-2024 (USD MILLION)
TABLE 76. GLOBAL ORPHAN DRUGS MARKET SIZE, BY ADULT, BY REGION, 2025-2030 (USD MILLION)
TABLE 77. GLOBAL ORPHAN DRUGS MARKET SIZE, BY PEDIATRIC, BY REGION, 2018-2024 (USD MILLION)
TABLE 78. GLOBAL ORPHAN DRUGS MARKET SIZE, BY PEDIATRIC, BY REGION, 2025-2030 (USD MILLION)
TABLE 79. GLOBAL ORPHAN DRUGS MARKET SIZE, BY PAYER TYPE, 2018-2024 (USD MILLION)
TABLE 80. GLOBAL ORPHAN DRUGS MARKET SIZE, BY PAYER TYPE, 2025-2030 (USD MILLION)
TABLE 81. GLOBAL ORPHAN DRUGS MARKET SIZE, BY GOVERNMENT PROGRAMS, BY REGION, 2018-2024 (USD MILLION)
TABLE 82. GLOBAL ORPHAN DRUGS MARKET SIZE, BY GOVERNMENT PROGRAMS, BY REGION, 2025-2030 (USD MILLION)
TABLE 83. GLOBAL ORPHAN DRUGS MARKET SIZE, BY OUT-OF-POCKET, BY REGION, 2018-2024 (USD MILLION)
TABLE 84. GLOBAL ORPHAN DRUGS MARKET SIZE, BY OUT-OF-POCKET, BY REGION, 2025-2030 (USD MILLION)
TABLE 85. GLOBAL ORPHAN DRUGS MARKET SIZE, BY PRIVATE INSURANCE, BY REGION, 2018-2024 (USD MILLION)
TABLE 86. GLOBAL ORPHAN DRUGS MARKET SIZE, BY PRIVATE INSURANCE, BY REGION, 2025-2030 (USD MILLION)
TABLE 87. AMERICAS ORPHAN DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2024 (USD MILLION)
TABLE 88. AMERICAS ORPHAN DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2025-2030 (USD MILLION)
TABLE 89. AMERICAS ORPHAN DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 90. AMERICAS ORPHAN DRUGS MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 91. AMERICAS ORPHAN DRUGS MARKET SIZE, BY BIOLOGICS, 2018-2024 (USD MILLION)
TABLE 92. AMERICAS ORPHAN DRUGS MARKET SIZE, BY BIOLOGICS, 2025-2030 (USD MILLION)
TABLE 93. AMERICAS ORPHAN DRUGS MARKET SIZE, BY GENE THERAPY, 2018-2024 (USD MILLION)
TABLE 94. AMERICAS ORPHAN DRUGS MARKET SIZE, BY GENE THERAPY, 2025-2030 (USD MILLION)
TABLE 95. AMERICAS ORPHAN DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2024 (USD MILLION)
TABLE 96. AMERICAS ORPHAN DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2025-2030 (USD MILLION)
TABLE 97. AMERICAS ORPHAN DRUGS MARKET SIZE, BY INJECTABLE, 2018-2024 (USD MILLION)
TABLE 98. AMERICAS ORPHAN DRUGS MARKET SIZE, BY INJECTABLE, 2025-2030 (USD MILLION)
TABLE 99. AMERICAS ORPHAN DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 100. AMERICAS ORPHAN DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 101. AMERICAS ORPHAN DRUGS MARKET SIZE, BY PATIENT TYPE, 2018-2024 (USD MILLION)
TABLE 102. AMERICAS ORPHAN DRUGS MARKET SIZE, BY PATIENT TYPE, 2025-2030 (USD MILLION)
TABLE 103. AMERICAS ORPHAN DRUGS MARKET SIZE, BY PAYER TYPE, 2018-2024 (USD MILLION)
TABLE 104. AMERICAS ORPHAN DRUGS MARKET SIZE, BY PAYER TYPE, 2025-2030 (USD MILLION)
TABLE 105. AMERICAS ORPHAN DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 106. AMERICAS ORPHAN DRUGS MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 107. UNITED STATES ORPHAN DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2024 (USD MILLION)
TABLE 108. UNITED STATES ORPHAN DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2025-2030 (USD MILLION)
TABLE 109. UNITED STATES ORPHAN DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 110. UNITED STATES ORPHAN DRUGS MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 111. UNITED STATES ORPHAN DRUGS MARKET SIZE, BY BIOLOGICS, 2018-2024 (USD MILLION)
TABLE 112. UNITED STATES ORPHAN DRUGS MARKET SIZE, BY BIOLOGICS, 2025-2030 (USD MILLION)
TABLE 113. UNITED STATES ORPHAN DRUGS MARKET SIZE, BY GENE THERAPY, 2018-2024 (USD MILLION)
TABLE 114. UNITED STATES ORPHAN DRUGS MARKET SIZE, BY GENE THERAPY, 2025-2030 (USD MILLION)
TABLE 115. UNITED STATES ORPHAN DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2024 (USD MILLION)
TABLE 116. UNITED STATES ORPHAN DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2025-2030 (USD MILLION)
TABLE 117. UNITED STATES ORPHAN DRUGS MARKET SIZE, BY INJECTABLE, 2018-2024 (USD MILLION)
TABLE 118. UNITED STATES ORPHAN DRUGS MARKET SIZE, BY INJECTABLE, 2025-2030 (USD MILLION)
TABLE 119. UNITED STATES ORPHAN DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 120. UNITED STATES ORPHAN DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 121. UNITED STATES ORPHAN DRUGS MARKET SIZE, BY PATIENT TYPE, 2018-2024 (USD MILLION)
TABLE 122. UNITED STATES ORPHAN DRUGS MARKET SIZE, BY PATIENT TYPE, 2025-2030 (USD MILLION)
TABLE 123. UNITED STATES ORPHAN DRUGS MARKET SIZE, BY PAYER TYPE, 2018-2024 (USD MILLION)
TABLE 124. UNITED STATES ORPHAN DRUGS MARKET SIZE, BY PAYER TYPE, 2025-2030 (USD MILLION)
TABLE 125. UNITED STATES ORPHAN DRUGS MARKET SIZE, BY STATE, 2018-2024 (USD MILLION)
TABLE 126. UNITED STATES ORPHAN DRUGS MARKET SIZE, BY STATE, 2025-2030 (USD MILLION)
TABLE 127. CANADA ORPHAN DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2024 (USD MILLION)
TABLE 128. CANADA ORPHAN DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2025-2030 (USD MILLION)
TABLE 129. CANADA ORPHAN DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 130. CANADA ORPHAN DRUGS MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 131. CANADA ORPHAN DRUGS MARKET SIZE, BY BIOLOGICS, 2018-2024 (USD MILLION)
TABLE 132. CANADA ORPHAN DRUGS MARKET SIZE, BY BIOLOGICS, 2025-2030 (USD MILLION)
TABLE 133. CANADA ORPHAN DRUGS MARKET SIZE, BY GENE THERAPY, 2018-2024 (USD MILLION)
TABLE 134. CANADA ORPHAN DRUGS MARKET SIZE, BY GENE THERAPY, 2025-2030 (USD MILLION)
TABLE 135. CANADA ORPHAN DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2024 (USD MILLION)
TABLE 136. CANADA ORPHAN DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2025-2030 (USD MILLION)
TABLE 137. CANADA ORPHAN DRUGS MARKET SIZE, BY INJECTABLE, 2018-2024 (USD MILLION)
TABLE 138. CANADA ORPHAN DRUGS MARKET SIZE, BY INJECTABLE, 2025-2030 (USD MILLION)
TABLE 139. CANADA ORPHAN DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 140. CANADA ORPHAN DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 141. CANADA ORPHAN DRUGS MARKET SIZE, BY PATIENT TYPE, 2018-2024 (USD MILLION)
TABLE 142. CANADA ORPHAN DRUGS MARKET SIZE, BY PATIENT TYPE, 2025-2030 (USD MILLION)
TABLE 143. CANADA ORPHAN DRUGS MARKET SIZE, BY PAYER TYPE, 2018-2024 (USD MILLION)
TABLE 144. CANADA ORPHAN DRUGS MARKET SIZE, BY PAYER TYPE, 2025-2030 (USD MILLION)
TABLE 145. MEXICO ORPHAN DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2024 (USD MILLION)
TABLE 146. MEXICO ORPHAN DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2025-2030 (USD MILLION)
TABLE 147. MEXICO ORPHAN DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 148. MEXICO ORPHAN DRUGS MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 149. MEXICO ORPHAN DRUGS MARKET SIZE, BY BIOLOGICS, 2018-2024 (USD MILLION)
TABLE 150. MEXICO ORPHAN DRUGS MARKET SIZE, BY BIOLOGICS, 2025-2030 (USD MILLION)
TABLE 151. MEXICO ORPHAN DRUGS MARKET SIZE, BY GENE THERAPY, 2018-2024 (USD MILLION)
TABLE 152. MEXICO ORPHAN DRUGS MARKET SIZE, BY GENE THERAPY, 2025-2030 (USD MILLION)
TABLE 153. MEXICO ORPHAN DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2024 (USD MILLION)
TABLE 154. MEXICO ORPHAN DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2025-2030 (USD MILLION)
TABLE 155. MEXICO ORPHAN DRUGS MARKET SIZE, BY INJECTABLE, 2018-2024 (USD MILLION)
TABLE 156. MEXICO ORPHAN DRUGS MARKET SIZE, BY INJECTABLE, 2025-2030 (USD MILLION)
TABLE 157. MEXICO ORPHAN DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 158. MEXICO ORPHAN DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 159. MEXICO ORPHAN DRUGS MARKET SIZE, BY PATIENT TYPE, 2018-2024 (USD MILLION)
TABLE 160. MEXICO ORPHAN DRUGS MARKET SIZE, BY PATIENT TYPE, 2025-2030 (USD MILLION)
TABLE 161. MEXICO ORPHAN DRUGS MARKET SIZE, BY PAYER TYPE, 2018-2024 (USD MILLION)
TABLE 162. MEXICO ORPHAN DRUGS MARKET SIZE, BY PAYER TYPE, 2025-2030 (USD MILLION)
TABLE 163. BRAZIL ORPHAN DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2024 (USD MILLION)
TABLE 164. BRAZIL ORPHAN DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2025-2030 (USD MILLION)
TABLE 165. BRAZIL ORPHAN DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 166. BRAZIL ORPHAN DRUGS MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 167. BRAZIL ORPHAN DRUGS MARKET SIZE, BY BIOLOGICS, 2018-2024 (USD MILLION)
TABLE 168. BRAZIL ORPHAN DRUGS MARKET SIZE, BY BIOLOGICS, 2025-2030 (USD MILLION)
TABLE 169. BRAZIL ORPHAN DRUGS MARKET SIZE, BY GENE THERAPY, 2018-2024 (USD MILLION)
TABLE 170. BRAZIL ORPHAN DRUGS MARKET SIZE, BY GENE THERAPY, 2025-2030 (USD MILLION)
TABLE 171. BRAZIL ORPHAN DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2024 (USD MILLION)
TABLE 172. BRAZIL ORPHAN DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2025-2030 (USD MILLION)
TABLE 173. BRAZIL ORPHAN DRUGS MARKET SIZE, BY INJECTABLE, 2018-2024 (USD MILLION)
TABLE 174. BRAZIL ORPHAN DRUGS MARKET SIZE, BY INJECTABLE, 2025-2030 (USD MILLION)
TABLE 175. BRAZIL ORPHAN DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 176. BRAZIL ORPHAN DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 177. BRAZIL ORPHAN DRUGS MARKET SIZE, BY PATIENT TYPE, 2018-2024 (USD MILLION)
TABLE 178. BRAZIL ORPHAN DRUGS MARKET SIZE, BY PATIENT TYPE, 2025-2030 (USD MILLION)
TABLE 179. BRAZIL ORPHAN DRUGS MARKET SIZE, BY PAYER TYPE, 2018-2024 (USD MILLION)
TABLE 180. BRAZIL ORPHAN DRUGS MARKET SIZE, BY PAYER TYPE, 2025-2030 (USD MILLION)
TABLE 181. ARGENTINA ORPHAN DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2024 (USD MILLION)
TABLE 182. ARGENTINA ORPHAN DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2025-2030 (USD MILLION)
TABLE 183. ARGENTINA ORPHAN DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 184. ARGENTINA ORPHAN DRUGS MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 185. ARGENTINA ORPHAN DRUGS MARKET SIZE, BY BIOLOGICS, 2018-2024 (USD MILLION)
TABLE 186. ARGENTINA ORPHAN DRUGS MARKET SIZE, BY BIOLOGICS, 2025-2030 (USD MILLION)
TABLE 187. ARGENTINA ORPHAN DRUGS MARKET SIZE, BY GENE THERAPY, 2018-2024 (USD MILLION)
TABLE 188. ARGENTINA ORPHAN DRUGS MARKET SIZE, BY GENE THERAPY, 2025-2030 (USD MILLION)
TABLE 189. ARGENTINA ORPHAN DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2024 (USD MILLION)
TABLE 190. ARGENTINA ORPHAN DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2025-2030 (USD MILLION)
TABLE 191. ARGENTINA ORPHAN DRUGS MARKET SIZE, BY INJECTABLE, 2018-2024 (USD MILLION)
TABLE 192. ARGENTINA ORPHAN DRUGS MARKET SIZE, BY INJECTABLE, 2025-2030 (USD MILLION)
TABLE 193. ARGENTINA ORPHAN DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 194. ARGENTINA ORPHAN DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 195. ARGENTINA ORPHAN DRUGS MARKET SIZE, BY PATIENT TYPE, 2018-2024 (USD MILLION)
TABLE 196. ARGENTINA ORPHAN DRUGS MARKET SIZE, BY PATIENT TYPE, 2025-2030 (USD MILLION)
TABLE 197. ARGENTINA ORPHAN DRUGS MARKET SIZE, BY PAYER TYPE, 2018-2024 (USD MILLION)
TABLE 198. ARGENTINA ORPHAN DRUGS MARKET SIZE, BY PAYER TYPE, 2025-2030 (USD MILLION)
TABLE 199. EUROPE, MIDDLE EAST & AFRICA ORPHAN DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2024 (USD MILLION)
TABLE 200. EUROPE, MIDDLE EAST & AFRICA ORPHAN DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2025-2030 (USD MILLION)
TABLE 201. EUROPE, MIDDLE EAST & AFRICA ORPHAN DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 202. EUROPE, MIDDLE EAST & AFRICA ORPHAN DRUGS MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 203. EUROPE, MIDDLE EAST & AFRICA ORPHAN DRUGS MARKET SIZE, BY BIOLOGICS, 2018-2024 (USD MILLION)
TABLE 204. EUROPE, MIDDLE EAST & AFRICA ORPHAN DRUGS MARKET SIZE, BY BIOLOGICS, 2025-2030 (USD MILLION)
TABLE 205. EUROPE, MIDDLE EAST & AFRICA ORPHAN DRUGS MARKET SIZE, BY GENE THERAPY, 2018-2024 (USD MILLION)
TABLE 206. EUROPE, MIDDLE EAST & AFRICA ORPHAN DRUGS MARKET SIZE, BY GENE THERAPY, 2025-2030 (USD MILLION)
TABLE 207. EUROPE, MIDDLE EAST & AFRICA ORPHAN DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2024 (USD MILLION)
TABLE 208. EUROPE, MIDDLE EAST & AFRICA ORPHAN DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2025-2030 (USD MILLION)
TABLE 209. EUROPE, MIDDLE EAST & AFRICA ORPHAN DRUGS MARKET SIZE, BY INJECTABLE, 2018-2024 (USD MILLION)
TABLE 210. EUROPE, MIDDLE EAST & AFRICA ORPHAN DRUGS MARKET SIZE, BY INJECTABLE, 2025-2030 (USD MILLION)
TABLE 211. EUROPE, MIDDLE EAST & AFRICA ORPHAN DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 212. EUROPE, MIDDLE EAST & AFRICA ORPHAN DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 213. EUROPE, MIDDLE EAST & AFRICA ORPHAN DRUGS MARKET SIZE, BY PATIENT TYPE, 2018-2024 (USD MILLION)
TABLE 214. EUROPE, MIDDLE EAST & AFRICA ORPHAN DRUGS MARKET SIZE, BY PATIENT TYPE, 2025-2030 (USD MILLION)
TABLE 215. EUROPE, MIDDLE EAST & AFRICA ORPHAN DRUGS MARKET SIZE, BY PAYER TYPE, 2018-2024 (USD MILLION)
TABLE 216. EUROPE, MIDDLE EAST & AFRICA ORPHAN DRUGS MARKET SIZE, BY PAYER TYPE, 2025-2030 (USD MILLION)
TABLE 217. EUROPE, MIDDLE EAST & AFRICA ORPHAN DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 218. EUROPE, MIDDLE EAST & AFRICA ORPHAN DRUGS MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 219. UNITED KINGDOM ORPHAN DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2024 (USD MILLION)
TABLE 220. UNITED KINGDOM ORPHAN DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2025-2030 (USD MILLION)
TABLE 221. UNITED KINGDOM ORPHAN DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 222. UNITED KINGDOM ORPHAN DRUGS MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 223. UNITED KINGDOM ORPHAN DRUGS MARKET SIZE, BY BIOLOGICS, 2018-2024 (USD MILLION)
TABLE 224. UNITED KINGDOM ORPHAN DRUGS MARKET SIZE, BY BIOLOGICS, 2025-2030 (USD MILLION)
TABLE 225. UNITED KINGDOM ORPHAN DRUGS MARKET SIZE, BY GENE THERAPY, 2018-2024 (USD MILLION)
TABLE 226. UNITED KINGDOM ORPHAN DRUGS MARKET SIZE, BY GENE THERAPY, 2025-2030 (USD MILLION)
TABLE 227. UNITED KINGDOM ORPHAN DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2024 (USD MILLION)
TABLE 228. UNITED KINGDOM ORPHAN DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2025-2030 (USD MILLION)
TABLE 229. UNITED KINGDOM ORPHAN DRUGS MARKET SIZE, BY INJECTABLE, 2018-2024 (USD MILLION)
TABLE 230. UNITED KINGDOM ORPHAN DRUGS MARKET SIZE, BY INJECTABLE, 2025-2030 (USD MILLION)
TABLE 231. UNITED KINGDOM ORPHAN DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 232. UNITED KINGDOM ORPHAN DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 233. UNITED KINGDOM ORPHAN DRUGS MARKET SIZE, BY PATIENT TYPE, 2018-2024 (USD MILLION)
TABLE 234. UNITED KINGDOM ORPHAN DRUGS MARKET SIZE, BY PATIENT TYPE, 2025-2030 (USD MILLION)
TABLE 235. UNITED KINGDOM ORPHAN DRUGS MARKET SIZE, BY PAYER TYPE, 2018-2024 (USD MILLION)
TABLE 236. UNITED KINGDOM ORPHAN DRUGS MARKET SIZE, BY PAYER TYPE, 2025-2030 (USD MILLION)
TABLE 237. GERMANY ORPHAN DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2024 (USD MILLION)
TABLE 238. GERMANY ORPHAN DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2025-2030 (USD MILLION)
TABLE 239. GERMANY ORPHAN DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 240. GERMANY ORPHAN DRUGS MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 241. GERMANY ORPHAN DRUGS MARKET SIZE, BY BIOLOGICS, 2018-2024 (USD MILLION)
TABLE 242. GERMANY ORPHAN DRUGS MARKET SIZE, BY BIOLOGICS, 2025-2030 (USD MILLION)
TABLE 243. GERMANY ORPHAN DRUGS MARKET SIZE, BY GENE THERAPY, 2018-2024 (USD MILLION)
TABLE 244. GERMANY ORPHAN DRUGS MARKET SIZE, BY GENE THERAPY, 2025-2030 (USD MILLION)
TABLE 245. GERMANY ORPHAN DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2024 (USD MILLION)
TABLE 246. GERMANY ORPHAN DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2025-2030 (USD MILLION)
TABLE 247. GERMANY ORPHAN DRUGS MARKET SIZE, BY INJECTABLE, 2018-2024 (USD MILLION)
TABLE 248. GERMANY ORPHAN DRUGS MARKET SIZE, BY INJECTABLE, 2025-2030 (USD MILLION)
TABLE 249. GERMANY ORPHAN DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 250. GERMANY ORPHAN DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 251. GERMANY ORPHAN DRUGS MARKET SIZE, BY PATIENT TYPE, 2018-2024 (USD MILLION)
TABLE 252. GERMANY ORPHAN DRUGS MARKET SIZE, BY PATIENT TYPE, 2025-2030 (USD MILLION)
TABLE 253. GERMANY ORPHAN DRUGS MARKET SIZE, BY PAYER TYPE, 2018-2024 (USD MILLION)
TABLE 254. GERMANY ORPHAN DRUGS MARKET SIZE, BY PAYER TYPE, 2025-2030 (USD MILLION)
TABLE 255. FRANCE ORPHAN DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2024 (USD MILLION)
TABLE 256. FRANCE ORPHAN DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2025-2030 (USD MILLION)
TABLE 257. FRANCE ORPHAN DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 258. FRANCE ORPHAN DRUGS MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 259. FRANCE ORPHAN DRUGS MARKET SIZE, BY BIOLOGICS, 2018-2024 (USD MILLION)
TABLE 260. FRANCE ORPHAN DRUGS MARKET SIZE, BY BIOLOGICS, 2025-2030 (USD MILLION)
TABLE 261. FRANCE ORPHAN DRUGS MARKET SIZE, BY GENE THERAPY, 2018-2024 (USD MILLION)
TABLE 262. FRANCE ORPHAN DRUGS MARKET SIZE, BY GENE THERAPY, 2025-2030 (USD MILLION)
TABLE 263. FRANCE ORPHAN DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2024 (USD MILLION)
TABLE 264. FRANCE ORPHAN DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2025-2030 (USD MILLION)
TABLE 265. FRANCE ORPHAN DRUGS MARKET SIZE, BY INJECTABLE, 2018-2024 (USD MILLION)
TABLE 266. FRANCE ORPHAN DRUGS MARKET SIZE, BY INJECTABLE, 2025-2030 (USD MILLION)
TABLE 267. FRANCE ORPHAN DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 268. FRANCE ORPHAN DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 269. FRANCE ORPHAN DRUGS MARKET SIZE, BY PATIENT TYPE, 2018-2024 (USD MILLION)
TABLE 270. FRANCE ORPHAN DRUGS MARKET SIZE, BY PATIENT TYPE, 2025-2030 (USD MILLION)
TABLE 271. FRANCE ORPHAN DRUGS MARKET SIZE, BY PAYER TYPE, 2018-2024 (USD MILLION)
TABLE 272. FRANCE ORPHAN DRUGS MARKET SIZE, BY PAYER TYPE, 2025-2030 (USD MILLION)
TABLE 273. RUSSIA ORPHAN DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2024 (USD MILLION)
TABLE 274. RUSSIA ORPHAN DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2025-2030 (USD MILLION)
TABLE 275. RUSSIA ORPHAN DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 276. RUSSIA ORPHAN DRUGS MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 277. RUSSIA ORPHAN DRUGS MARKET SIZE, BY BIOLOGICS, 2018-2024 (USD MILLION)
TABLE 278. RUSSIA ORPHAN DRUGS MARKET SIZE, BY BIOLOGICS, 2025-2030 (USD MILLION)
TABLE 279. RUSSIA ORPHAN DRUGS MARKET SIZE, BY GENE THERAPY, 2018-2024 (USD MILLION)
TABLE 280. RUSSIA ORPHAN DRUGS MARKET SIZE, BY GENE THERAPY, 2025-2030 (USD MILLION)
TABLE 281. RUSSIA ORPHAN DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2024 (USD MILLION)
TABLE 282. RUSSIA ORPHAN DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2025-2030 (USD MILLION)
TABLE 283. RUSSIA ORPHAN DRUGS MARKET SIZE, BY INJECTABLE, 2018-2024 (USD MILLION)
TABLE 284. RUSSIA ORPHAN DRUGS MARKET SIZE, BY INJECTABLE, 2025-2030 (USD MILLION)
TABLE 285. RUSSIA ORPHAN DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 286. RUSSIA ORPHAN DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 287. RUSSIA ORPHAN DRUGS MARKET SIZE, BY PATIENT TYPE, 2018-2024 (USD MILLION)
TABLE 288. RUSSIA ORPHAN DRUGS MARKET SIZE, BY PATIENT TYPE, 2025-2030 (USD MILLION)
TABLE 289. RUSSIA ORPHAN DRUGS MARKET SIZE, BY PAYER TYPE, 2018-2024 (USD MILLION)
TABLE 290. RUSSIA ORPHAN DRUGS MARKET SIZE, BY PAYER TYPE, 2025-2030 (USD MILLION)
TABLE 291. ITALY ORPHAN DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2024 (USD MILLION)
TABLE 292. ITALY ORPHAN DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2025-2030 (USD MILLION)
TABLE 293. ITALY ORPHAN DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 294. ITALY ORPHAN DRUGS MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 295. ITALY ORPHAN DRUGS MARKET SIZE, BY BIOLOGICS, 2018-2024 (USD MILLION)
TABLE 296. ITALY ORPHAN DRUGS MARKET SIZE, BY BIOLOGICS, 2025-2030 (USD MILLION)
TABLE 297. ITALY ORPHAN DRUGS MARKET SIZE, BY GENE THERAPY, 2018-2024 (USD MILLION)
TABLE 298. ITALY ORPHAN DRUGS MARKET SIZE, BY GENE THERAPY, 2025-2030 (USD MILLION)
TABLE 299. ITALY ORPHAN DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2024 (USD MILLION)
TABLE 300. ITALY ORPHAN DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2025-2030 (USD MILLION)
TABLE 301. ITALY ORPHAN DRUGS MARKET SIZE, BY INJECTABLE, 2018-2024 (USD MILLION)
TABLE 302. ITALY ORPHAN DRUGS MARKET SIZE, BY INJECTABLE, 2025-2030 (USD MILLION)
TABLE 303. ITALY ORPHAN DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 304. ITALY ORPHAN DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 305. ITALY ORPHAN DRUGS MARKET SIZE, BY PATIENT TYPE, 2018-2024 (USD MILLION)
TABLE 306. ITALY ORPHAN DRUGS MARKET SIZE, BY PATIENT TYPE, 2025-2030 (USD MILLION)
TABLE 307. ITALY ORPHAN DRUGS MARKET SIZE, BY PAYER TYPE, 2018-2024 (USD MILLION)
TABLE 308. ITALY ORPHAN DRUGS MARKET SIZE, BY PAYER TYPE, 2025-2030 (USD MILLION)
TABLE 309. SPAIN ORPHAN DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2024 (USD MILLION)
TABLE 310. SPAIN ORPHAN DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2025-2030 (USD MILLION)
TABLE 311. SPAIN ORPHAN DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 312. SPAIN ORPHAN DRUGS MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 313. SPAIN ORPHAN DRUGS MARKET SIZE, BY BIOLOGICS, 2018-2024 (USD MILLION)
TABLE 314. SPAIN ORPHAN DRUGS MARKET SIZE, BY BIOLOGICS, 2025-2030 (USD MILLION)
TABLE 315. SPAIN ORPHAN DRUGS MARKET SIZE, BY GENE THERAPY, 2018-2024 (USD MILLION)
TABLE 316. SPAIN ORPHAN DRUGS MARKET SIZE, BY GENE THERAPY, 2025-2030 (USD MILLION)
TABLE 317. SPAIN ORPHAN DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2024 (USD MILLION)
TABLE 318. SPAIN ORPHAN DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2025-2030 (USD MILLION)
TABLE 319. SPAIN ORPHAN DRUGS MARKET SIZE, BY INJECTABLE, 2018-2024 (USD MILLION)
TABLE 320. SPAIN ORPHAN DRUGS MARKET SIZE, BY INJECTABLE, 2025-2030 (USD MILLION)
TABLE 321. SPAIN ORPHAN DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 322. SPAIN ORPHAN DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 323. SPAIN ORPHAN DRUGS MARKET SIZE, BY PATIENT TYPE, 2018-2024 (USD MILLION)
TABLE 324. SPAIN ORPHAN DRUGS MARKET SIZE, BY PATIENT TYPE, 2025-2030 (USD MILLION)
TABLE 325. SPAIN ORPHAN DRUGS MARKET SIZE, BY PAYER TYPE, 2018-2024 (USD MILLION)
TABLE 326. SPAIN ORPHAN DRUGS MARKET SIZE, BY PAYER TYPE, 2025-2030 (USD MILLION)
TABLE 327. UNITED ARAB EMIRATES ORPHAN DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2024 (USD MILLION)
TABLE 328. UNITED ARAB EMIRATES ORPHAN DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2025-2030 (USD MILLION)
TABLE 329. UNITED ARAB EMIRATES ORPHAN DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 330. UNITED ARAB EMIRATES ORPHAN DRUGS MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 331. UNITED ARAB EMIRATES ORPHAN DRUGS MARKET SIZE, BY BIOLOGICS, 2018-2024 (USD MILLION)
TABLE 332. UNITED ARAB EMIRATES ORPHAN DRUGS MARKET SIZE, BY BIOLOGICS, 2025-2030 (USD MILLION)
TABLE 333. UNITED ARAB EMIRATES ORPHAN DRUGS MARKET SIZE, BY GENE THERAPY, 2018-2024 (USD MILLION)
TABLE 334. UNITED ARAB EMIRATES ORPHAN DRUGS MARKET SIZE, BY GENE THERAPY, 2025-2030 (USD MILLION)
TABLE 335. UNITED ARAB EMIRATES ORPHAN DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2024 (USD MILLION)
TABLE 336. UNITED ARAB EMIRATES ORPHAN DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2025-2030 (USD MILLION)
TABLE 337. UNITED ARAB EMIRATES ORPHAN DRUGS MARKET SIZE, BY INJECTABLE, 2018-2024 (USD MILLION)
TABLE 338. UNITED ARAB EMIRATES ORPHAN DRUGS MARKET SIZE, BY INJECTABLE, 2025-2030 (USD MILLION)
TABLE 339. UNITED ARAB EMIRATES ORPHAN DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 340. UNITED ARAB EMIRATES ORPHAN DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 341. UNITED ARAB EMIRATES ORPHAN DRUGS MARKET SIZE, BY PATIENT TYPE, 2018-2024 (USD MILLION)
TABLE 342. UNITED ARAB EMIRATES ORPHAN DRUGS MARKET SIZE, BY PATIENT TYPE, 2025-2030 (USD MILLION)
TABLE 343. UNITED ARAB EMIRATES ORPHAN DRUGS MARKET SIZE, BY PAYER TYPE, 2018-2024 (USD MILLION)
TABLE 344. UNITED ARAB EMIRATES ORPHAN DRUGS MARKET SIZE, BY PAYER TYPE, 2025-2030 (USD MILLION)
TABLE 345. SAUDI ARABIA ORPHAN DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2024 (USD MILLION)
TABLE 346. SAUDI ARABIA ORPHAN DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2025-2030 (USD MILLION)
TABLE 347. SAUDI ARABIA ORPHAN DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 348. SAUDI ARABIA ORPHAN DRUGS MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 349. SAUDI ARABIA ORPHAN DRUGS MARKET SIZE, BY BIOLOGICS, 2018-2024 (USD MILLION)
TABLE 350. SAUDI ARABIA ORPHAN DRUGS MARKET SIZE, BY BIOLOGICS, 2025-2030 (USD MILLION)
TABLE 351. SAUDI ARABIA ORPHAN DRUGS MARKET SIZE, BY GENE THERAPY, 2018-2024 (USD MILLION)
TABLE 352. SAUDI ARABIA ORPHAN DRUGS MARKET SIZE, BY GENE THERAPY, 2025-2030 (USD MILLION)
TABLE 353. SAUDI ARABIA ORPHAN DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2024 (USD MILLION)
TABLE 354. SAUDI ARABIA ORPHAN DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2025-2030 (USD MILLION)
TABLE 355. SAUDI ARABIA ORPHAN DRUGS MARKET SIZE, BY INJECTABLE, 2018-2024 (USD MILLION)
TABLE 356. SAUDI ARABIA ORPHAN DRUGS MARKET SIZE, BY INJECTABLE, 2025-2030 (USD MILLION)
TABLE 357. SAUDI ARABIA ORPHAN DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 358. SAUDI ARABIA ORPHAN DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 359. SAUDI ARABIA ORPHAN DRUGS MARKET SIZE, BY PATIENT TYPE, 2018-2024 (USD MILLION)
TABLE 360. SAUDI ARABIA ORPHAN DRUGS MARKET SIZE, BY PATIENT TYPE, 2025-2030 (USD MILLION)
TABLE 361. SAUDI ARABIA ORPHAN DRUGS MARKET SIZE, BY PAYER TYPE, 2018-2024 (USD MILLION)
TABLE 362. SAUDI ARABIA ORPHAN DRUGS MARKET SIZE, BY PAY

Samples

Loading
LOADING...

Companies Mentioned

  • F. Hoffmann-La Roche Ltd
  • Johnson & Johnson
  • Novartis AG
  • Pfizer Inc.
  • Sanofi S.A.
  • Bristol-Myers Squibb Company
  • Amgen Inc.
  • Takeda Pharmaceutical Company Limited
  • AbbVie Inc.
  • BioMarin Pharmaceutical Inc.

Table Information

Report AttributeDetails
No. of Pages187
PublishedAugust 2025
Forecast Period2025 - 2030
Estimated Market Value ( USD ) in 2025 $ 246.85 Billion
Forecasted Market Value ( USD ) by 2030 $ 463.09 Billion
Compound Annual Growth Rate13.4%
Regions CoveredGlobal
No. of Companies Mentioned10

Related Topics

Related Reports

Orphan Drugs - Global Strategic Business Report - Product Image

Orphan Drugs - Global Strategic Business Report

  • Report
  • 409 Pages
  • Global
From
Orphan Drugs Market Report by Drug Type, Disease Type, Phase, Top Selling Drugs, Distribution Channel, and Region 2025-2033 - Product Image

Orphan Drugs Market Report by Drug Type, Disease Type, Phase, Top Selling Drugs, Distribution Channel, and Region 2025-2033

  • Report
  • 148 Pages
  • Global
From
Orphan Drugs Market Report 2025 - Product Image

Orphan Drugs Market Report 2025

  • Report
  • 175 Pages
  • Global
From
Drug Discovery Services Market by Process (Target Validation, Hit-to-Lead, Lead Optimization), Type (Chemistry, Biology), Therapeutic Area (Oncology, Neurology, Infectious, CVD), Drug Type (Small Molecules, Biologics), End User - Global Forecast to 2030 - Product Image

Drug Discovery Services Market by Process (Target Validation, Hit-to-Lead, Lead Optimization), Type (Chemistry, Biology), Therapeutic Area (Oncology, Neurology, Infectious, CVD), Drug Type (Small Molecules, Biologics), End User - Global Forecast to 2030

  • Report
  • 451 Pages
  • Global
From
Small Molecule Drug Discovery - Global Strategic Business Report - Product Image

Small Molecule Drug Discovery - Global Strategic Business Report

  • Report
  • 376 Pages
  • Global
From

About the Orphan Drug Market

The Orphan Drug market is a subset of the Pharmaceutical industry that focuses on the development and commercialization of drugs for rare diseases. These drugs are typically developed to treat diseases that affect fewer than 200,000 people in the United States. The Orphan Drug Act of 1983 was passed to incentivize the development of these drugs by providing tax credits, grants, and other incentives to companies that develop them. The Orphan Drug market has grown significantly in recent years, with more companies entering the market and more drugs being developed. This growth has been driven by advances in medical technology, increased public awareness of rare diseases, and the availability of government incentives. Some companies in the Orphan Drug market include AbbVie, Amgen, Biogen, Gilead Sciences, and Novartis. Show Less Read more

Copyright © 2002-2025 Research and Markets. All Rights Reserved.